Home/Pipeline/Unnamed AATD Program

Unnamed AATD Program

Alpha-1 Antitrypsin Deficiency (AATD)

Pre-clinicalLead Program

Key Facts

Indication

Alpha-1 Antitrypsin Deficiency (AATD)

Phase

Pre-clinical

Status

Lead Program

Company

AlveoGene

About AlveoGene

AlveoGene is an innovative biotech focused on transforming outcomes for patients with rare respiratory diseases through targeted, inhaled gene therapy. Its core asset is the InGenuiTy™ platform, a next-generation lentiviral vector system designed for high-efficiency transduction of lung epithelial cells, enabling durable expression and repeatable dosing. The company was formed in July 2023 by a consortium of leading UK life science investors and six world-renowned scientific founders from the UK Respiratory Gene Therapy Consortium, leveraging over £72 million in prior grant-funded research.

View full company profile

Therapeutic Areas

Rare Respiratory Diseases Genetic Disorders Pulmonology

Other Alpha-1 Antitrypsin Deficiency (AATD) Drugs

Drug	Company	Phase	Status
NB-101	Nerai Biosciences	Pre-clinical	Active
Undisclosed	GondolaBio	IND Enabling	Active
TSRA-196	Tessera Therapeutics	Phase 1	Active
BEAM-302 (for Beam Therapeutics)	Richmond Pharmacology	Phase 1/2	Active
KB408	Krystal Biotech	Preclinical	Active
Alpha-1 Antitrypsin (AAT)	Grifols	Marketed	Lifecycle Management
BEAM-302	Beam Therapeutics	Phase 1/2	Active
GalNAc Program	Korro Bio	Preclinical	Active